Ludwig Institute for Cancer Research Limited

Universitè Catholique De Louvain

Argenx Bvba

Institut National De La Sante Et De La Recherche Medicale

Ludwig Institute for Cancer

Université Catholique De Louvian

Argenx Bv

Sophie Lucas

Thierry R Boon-Falleur

Pierre G Coulie

Charles De Smet

Sebastian Paul Van Der Woning

Gitte De Boeck

Jean-Christophe Renauld

Torsten Dreier

Vincent Brichard

Laure Dumoutier

Nicolas Van Baren

Charles DeSmet

Daniele Godelaine

Francine Jotereau

Lore Mariën

Yannick Guilloux

Filip Borgions

Julia Cuende Villasur

Hans De Haard

Michael Saunders

Bernard Lethe

Stéphanie Liénart

Sebastian Van Der Woning

Bernard Lethé

Stéphanie Lienart

Stëphanie Liénart

Stephanie Lienart

Lore Marien

Lore MARIËN

The present invention relates to a protein binding to GARP in the presence of TGF-&#x3b2; and uses thereof.

Anti-GARP protein

The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-&#x3b2;1, particularly a complex of human GARP and human TGF-&#x3b2;1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-&#x3b2; from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.

Nucleic acids encoding GARP-TGF-beta 1 antibodies

Method of screening for anti-GARP antibodies

GARP-TGF-&#x3b2; 1 IGG antibodies

Antibody against a complex between human GARP and latent TGF-&#x3b2;

GARP-TGF-beta 1 antibodies

The present invention relates to an antibody binding to the transmembrane protein 'glycoprotein A repetitions predominant' (GARP) in the presence of TGF-&#x3b2; and uses thereof.

Method for inhibiting the immune suppressive function of human T regulatory cells by administering an anti-GARP monoclonal antibody

The invention describes the LAGE-1 tumor associated gene, including fragments, allelic variants and splice variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LAGE-1 gene product.

Lage-1 tumor associated nucleic acids

LAGE-1 tumor associated nucleic acids

The invention relates to isolated nucleic acid molecules which code for antigens expressed by tumor cells which maybe recognized by cytotoxic T cells, leading to lysis of the tumor cells which express it. This invention also relates to vectors which are designed to encode the antigen expressed by tumor cells and also to cells transfected by the nucleic acid molecules or vectors which comprise the nucleic acid molecules. Various therapeutic and diagnostic uses arising out of the properties of the nucleic acid molecules and the antigens for which these code are also part of this invention.

Isolated nucleic acid molecule coding for tumor rejection antigen precursors MAGE-C1 and MAGE-C2 and uses thereof

The invention describes the LAGE-1 tumor associated gene, including fragments, allelic variants and splice variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LAGE-1 gene product.

Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof

The invention describes leukemia associated genes, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a preproTRH, tryptase-L and/or Oct-T1 gene product.

Leukemia associated genes

Growing community of inventors

Duisburg, Belgium

Sophie Lucas